At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
Trabectedindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS·interventional·Posted Dec 15, 2016·Updated Aug 25, 2021
In Brief
A Phase 2 clinical trial evaluating Trabectedin for Carcinosarcoma, Ovarian and Carcinosarcomas Uterine. Completed, enrolled 45 participants across 1 site.
Detailed Summary
Multicenter phase II study on trabectedin in patients advanced uterine and ovarian carcinosarcoma. Patients will receive trabectedin until disease progression or unacceptable toxicity. Disease response evaluation will be assessed every 9 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinosarcoma, Ovarian, Carcinosarcomas Uterine
CountriesItaly
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartFeb 2017
Primary CompletionNov 2019
TodayJul 2026
First PostedDec 15, 2016
Enrollment StartFeb 22, 2017
Primary CompletionNov 13, 2019
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 9.5 years ago
Interventions
Trabectedindrug
Chemotherapy drug